Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Firtecan pegol - Belrose Pharma

Drug Profile

Firtecan pegol - Belrose Pharma

Alternative Names: BEL-0222; EZN-2208; PEG-SN38; Pegylated-SN-38; SN38-PEG

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Belrose Pharma; Enzon Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Camptothecins; Polyethylene glycols
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer
  • Phase I/II Neuroblastoma; Solid tumours
  • Discontinued Lymphoma

Most Recent Events

  • 16 Jan 2024 Firtecan pegol is still in phase II trials for Colorectal cancer in Canada, Israel, Netherlands, the US and UK (IV) (Enzon Pharmaceuticals pipeline, January 2024)
  • 15 Jul 2013 Phase-I clinical trials in Solid tumours (combination therapy, metastatic disease) in USA (IV)
  • 15 Jul 2013 Phase-I/II clinical trials in Neuroblastoma (monotherapy, in infants, children and adolescents, second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top